Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251 is registered in ClinicalTrials.gov with R-Pharm Overseas, Inc. as lead sponsor.

NCT NCT04463251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04463251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
Lead sponsor
R-Pharm Overseas, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 7, 2020
Completion date
October 10, 2022
Enrollment
102 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute st segment elevation myocardial infarction